keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/28548129/central-pathology-review-with-two-stage-quality-assurance-for-pathological-response-after-neoadjuvant-chemotherapy-in-the-artemis-trial
#1
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, Janet Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Ioannis Gounaris, Jean Abraham, Luke Hughes-Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, Carlos Caldas, John Ms Bartlett, David Allan Cameron, Richard Laurence Hayward, Helena Margaret Earl
The ARTemis Trial tested standard neoadjuvant chemotherapy±bevacizumab in the treatment of HER2-negative early breast cancer. We compare data from central pathology review with report review and also the reporting behavior of the two central pathologists. Eight hundred women with HER2-negative early invasive breast cancer were recruited. Response to chemotherapy was assessed from local pathology reports for pathological complete response in breast and axillary lymph nodes. Sections from the original core biopsy and surgical excision were centrally reviewed by one of two trial pathologists blinded to the local pathology reports...
May 26, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28547976/prevalence-of-biological-types-of-breast-cancer-and-their-influence-on-disease-staging-and-therapeutic-management-a-single-center-study
#2
Tomasz Nowikiewicz, Ewa Chmielowska, Hanna Andrusewicz, Joanna Łysik-Miśkurka, Iwona Głowacka, Magdalena Sowa, Wojciech Zegarski
According to the St. Gallen 2011 consensus, proper qualification of breast cancer patients for treatment requires taking into consideration the division into biological types of neoplasms. The goal of this work was to assess the prevalence of all biological types of breast cancer in the population of Kuyavian-Pomeranian province. We determined the influence of particular types of neoplasms on the degree of disease progression and the choice of therapeutic management. The study was conducted on a group of 2653 patients treated surgically due to malignant breast tumors in the Oncology Centre in Bydgoszcz...
2017: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/28547525/neoadjuvant-chemotherapy-with-trastuzumab-docetaxel-and-carboplatin-administered-every-3%C3%A2-weeks-for-japanese-women-with-her2-positive-primary-breast-cancer-efficacy-and-safety
#3
Ikuko Sugitani, Shigeto Ueda, Takashi Sakurai, Takashi Shigekawa, Eiko Hirokawa, Hiroko Shimada, Hideki Takeuchi, Kazuo Matsuura, Misono Misumi, Nobuko Fujiuchi, Takao Takahashi, Takahiro Hasebe, Akihiko Osaki, Toshiaki Saeki
BACKGROUND: This phase II neoadjuvant study evaluated the efficacy and safety of a triweekly regimen of docetaxel and carboplatin in combination with trastuzumab (TCbH) in Japanese women with human epidermal growth factor receptor type2 (HER2)-positive primary breast cancer. METHODS: Patients with HER2-positive, stage I-III invasive breast cancer received six courses of trastuzumab (8 mg/kg loading dose, then 6 mg/kg, day 1), docetaxel (75 mg/m(2), day 1), and carboplatin (area under the curve: 6, day 1) every 3 weeks...
May 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28535650/-texture-analysis-based-on-contrast-enhanced-mri-can-predict-treatment-response-to-neoadjuvant-chemotherapy-of-breast-cancer
#4
S H Sun, C W Zhou, L Y Zhao, R Z Zhang, H Ouyang
Objective: To investigate whether texture analysis based on contrast-enhanced MRI can predict pathological complete response of locally advanced breast cancer undergoing neoadjuvant chemotherapy(NAC). Methods: Forty-seven patients with breast cancer undergone neoadjuvant chemotherapy from January 2015 to February 2016 were divided into pathological complete response (pCR) group or non-pathological complete response (non-pCR) group based on surgical pathology. Their parameters of texture analysis based on MRI before neoadjuvant chemotherapy and after 2 cycles of treatment were analyzed...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28532642/optical-mammography-in-patients-with-breast-cancer-undergoing-neoadjuvant-chemotherapy-individual-clinical-response-index
#5
Pamela G Anderson, Sirishma Kalli, Angelo Sassaroli, Nishanth Krishnamurthy, Shital S Makim, Roger A Graham, Sergio Fantini
RATIONALE AND OBJECTIVES: We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxyhemoglobin ([HbO2]), deoxyhemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time points during chemotherapy. MATERIALS AND METHODS: Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on 10 patients before treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12, range: 7-18)...
May 19, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28527420/factors-predictive-of-locoregional-recurrence-following-neoadjuvant-chemotherapy-in-patients-with-large-operable-or-locally-advanced-breast-cancer-an-analysis-of-the-eortc-10994-big-1-00-study
#6
Pauline Gillon, Nathan Touati, Christel Breton-Callu, Leen Slaets, David Cameron, Hervé Bonnefoi
PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines...
May 17, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28525810/tumor-infiltrating-lymphocytes-in-patients-with-her2-positive-breast-cancer-treated-with-neoadjuvant-chemotherapy-plus-trastuzumab-lapatinib-or-their-combination-a-meta-analysis-of-randomized-controlled-trials
#7
REVIEW
C Solinas, M Ceppi, M Lambertini, M Scartozzi, L Buisseret, S Garaud, D Fumagalli, E de Azambuja, R Salgado, C Sotiriou, K Willard-Gallo, M Ignatiadis
BACKGROUND: A relationship between baseline tumor-infiltrating lymphocytes (TIL) and outcomes has been described in HER2-positive breast cancer. Nevertheless, the magnitude of this association and whether this effect differs based on the type of anti-HER2 agent remain controversial. This meta-analysis investigated the association between baseline TIL and pathologic complete response (pCR) rates in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab and lapatinib either alone or in combination...
May 2, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28524246/combined-pet-ct-and-axillary-lymph-node-marking-with-radioactive-iodine-seeds-mari-procedure-for-tailored-axillary-treatment-in-node-positive-breast-cancer-after-neoadjuvant-therapy
#8
B B Koolen, M Donker, M E Straver, M E M van der Noordaa, E J T Rutgers, R A Valdés Olmos, M J T F D Vrancken Peeters
BACKGROUND: The treatment of axillary lymph node metastases after neoadjuvant systemic therapy (NST) remains debatable and axillary lymph node dissection (ALND) is still the standard of care. Marking axillary lymph nodes with radioactive iodine seeds (MARI procedure) is accurate in restaging the axilla after NST (false-negative rate 7 per cent). Here, the potential of tailored axillary treatment, determined by combining the results of PET-CT before NST with those of the MARI procedure after NST, was analysed...
May 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28523352/interim-heterogeneity-changes-measured-using-entropy-texture-features-on-t2-weighted-mri-at-3-0%C3%A2-t-are-associated-with-pathological-response-to-neoadjuvant-chemotherapy-in-primary-breast-cancer
#9
Shelley Henderson, Colin Purdie, Caroline Michie, Andrew Evans, Richard Lerski, Marilyn Johnston, Sarah Vinnicombe, Alastair M Thompson
OBJECTIVES: To investigate whether interim changes in hetereogeneity (measured using entropy features) on MRI were associated with pathological residual cancer burden (RCB) at final surgery in patients receiving neoadjuvant chemotherapy (NAC) for primary breast cancer. METHODS: This was a retrospective study of 88 consenting women (age: 30-79 years). Scanning was performed on a 3.0 T MRI scanner prior to NAC (baseline) and after 2-3 cycles of treatment (interim)...
May 18, 2017: European Radiology
https://www.readbyqxmd.com/read/28516441/decision-making-in-the-surgical-management-of-invasive-breast-cancer-part-2-expanded-applications-for-breast-conserving-surgery
#10
REVIEW
Lisa A Newman
Treatment of early-stage invasive breast cancer with breast-conserving surgery plus radiation therapy (RT) yields overall survival outcomes equivalent to those achieved with mastectomy. Further, breast-conserving surgery is endorsed by the National Comprehensive Cancer Network as being supported by the highest-level, category 1 evidence. Advances in pathologic evaluation, management of multiple tumors, oncoplastic lumpectomy techniques, neoadjuvant chemotherapy, and hypofractionated RT can expand the pool of patients eligible for breast-conserving surgery...
May 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28503722/fertility-preservation-with-ovarian-stimulation-and-time-to-treatment-in-women-with-stage-ii-iii-breast-cancer-receiving-neoadjuvant-therapy
#11
A Jo Chien, Julia Chambers, Fiona Mcauley, Tessa Kaplan, Joseph Letourneau, Jimmy Hwang, Mi-Ok Kim, Michelle E Melisko, Hope S Rugo, Laura J Esserman, Mitchell P Rosen
PURPOSE: To determine whether fertility preservation with ovarian stimulation (OS) results in treatment delay in breast cancer (BC) patients receiving neoadjuvant therapy (NAT). METHODS: This is a retrospective study of women screened for the prospective neoadjuvant ISPY2 trial at the University of California San Francisco. All patients were <43, had stage II-III BC, and received neoadjuvant therapy. Time to initiation of NAT was compared between women who underwent OS (STIM) and women who did not (control)...
May 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28488142/a-prospective-randomized-controlled-trial-of-hydrating-nail-solution-for-prevention-or-treatment-of-onycholysis-in-breast-cancer-patients-who-received-neoadjuvant-adjuvant-docetaxel-chemotherapy
#12
Ji-Yeon Kim, Oh Nam Ok, Jeong-Ju Seo, Soo-Hyeon Lee, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
PURPOSE: Onycholysis and other nail toxicities occur in approximately 20-30% of breast cancer (BC) patients receiving docetaxel chemotherapy. Onycholysis is often associated with painful paronychia, decreasing patients' quality of life. In this study, we aimed to evaluate the efficacy of hydrating nail solution (HNS) (EVONAIL(®) solution, Evaux Laboratories, France) for the prevention and treatment of docetaxel-induced onycholysis and nail toxicities. METHODS: This study was a prospective, randomized, controlled study of HNS for the prevention or treatment of onycholysis in patients with docetaxel after doxorubicin plus cyclophosphamide...
May 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28487444/the-longitudinal-transcriptional-response-to-neoadjuvant-chemotherapy-with-and-without-bevacizumab-in-breast-cancer
#13
Laxmi Silwal-Pandit, Silje Nord, Hedda von der Lippe Gythfeldt, Elen K Møller, Thomas Fleischer, Einar Rødland, Marit Krohn, Elin Borgen, Øystein Garred, Tone Olsen, Phuong Vu, Helle Skjerven, Anne Fangberget, Marit M Holmen, Ellen Schlichting, Elisabeth Wille, Mette Nordberg Stokke, Hans Kristian Moen Vollan, Vessela N Kristensen, Anita Langerød, Steinar Lundgren, Erik A Wist, Bjørn Naume, Ole Christian Lingjerde, Anne-Lise Borresen-Dale, Olav Engebraaten
Chemotherapy induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase II clinical trial to assess the effect of neoadjuvant chemotherapy with the addition of bevacizumab. <br />Experimental Design: Tumor biopsies and whole-transcriptome mRNA profiles were obtained at three fixed time points with 66 patients in each arm.  Altogether, 358 specimens from 132 patients were available, representing the transcriptional state before treatment start, at 12 weeks and after treatment (25 weeks)...
May 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28484211/metabolic-radiomics-for-pretreatment-18-f-fdg-pet-ct-to-characterize-locally-advanced-breast-cancer-histopathologic-characteristics-response-to-neoadjuvant-chemotherapy-and-prognosis
#14
Seunggyun Ha, Sohyun Park, Ji-In Bang, Eun-Kyu Kim, Ho-Young Lee
Radiomics has been spotlighted as imaging biomarker for estimation of intratumoral heterogeneity (ITH) which is regarded as the main reason for resistance to tumor treatment. Although a number of studies has shown clinical evidences that separate measurement of metabolic ITH by texture features (TFs) on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has prognostic ability in various tumors, there has been no consensus regarding the best parameter representing ITH...
May 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28484080/neoadjuvant-chemotherapy-increases-rates-of-breast-conserving-surgery-in-early-operable-breast-cancer
#15
V Cm Man, P Sy Cheung
INTRODUCTION: Neoadjuvant chemotherapy is commonly used in stage III breast cancer for disease down-staging. Its use has now been extended to early breast cancer to increase the rate of breast-conserving surgery. This study aimed to evaluate the effectiveness of neoadjuvant chemotherapy in early operable cancers. METHODS: A retrospective study was carried out at the Hong Kong Sanatorium & Hospital of 102 patients with stage I to III primary breast cancer. All patients who underwent neoadjuvant chemotherapy followed by definitive breast surgery between January 2004 and July 2013 were included...
May 9, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28481792/multiparametric-evaluation-of-treatment-response-to-neoadjuvant-chemotherapy-in-breast-cancer-using-integrated-pet-mr
#16
Jane Wang, Tiffany Ting-Fang Shih, Ruoh-Fang Yen
PURPOSE: The aim of this study was to investigate whether integrated PET/MR system can predict the treatment response to neoadjuvant chemotherapy (NAC) early in the course of breast cancer treatment. METHODS: Fourteen women with newly diagnosed invasive breast cancer (median age, 54.5 years) were recruited. Each participant underwent 2 PET/MR studies. Study 1 was pre-NAC; study 2 was early in NAC treatment (after the first or second cycle). PET parameters included SUVmax and total lesion glycolysis (TLG)...
May 6, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28481705/breast-reconstruction-with-postmastectomy-radiation-choices-and-tradeoffs
#17
Matthew M Poppe, Jayant P Agarwal
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28479096/comparing-the-therapeutic-potential-of-thermosensitive-liposomes-and-hyperthermia-in-two-distinct-subtypes-of-breast-cancer
#18
Wouter J M Lokerse, Michiel Bolkestein, Simone U Dalm, Alexander M M Eggermont, Marion de Jong, Holger Grüll, Gerben A Koning
Local drug delivery of Doxorubicin (Dox) with thermosensitive liposomes (TSL) and hyperthermia (HT) has shown preclinically to achieve high local drug concentrations with good therapeutic efficacy. Currently, this is clinically studied for treatment of chest wall recurrence of breast cancer, however with various outcomes. This study examines the potency of neoadjuvant TSL HT combination therapy in two orthotopic mouse models of human breast cancer, MDA-MB-231 and T-47D, which morphologically correlate to mesenchymal and epithelial phenotypes, respectively...
May 4, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28467142/monitoring-neoadjuvant-chemotherapy-for-breast-cancer-by-using-three-dimensional-subharmonic-aided-pressure-estimation-and-imaging-with-us-contrast-agents-preliminary-experience
#19
Kibo Nam, John R Eisenbrey, Maria Stanczak, Anush Sridharan, Adam C Berger, Tiffany Avery, Juan P Palazzo, Flemming Forsberg
Purpose To determine whether three-dimensional subharmonic aided pressure estimation (SHAPE) and subharmonic imaging can help predict the response of breast cancer to neoadjuvant chemotherapy. Materials and Methods In this HIPAA-compliant prospective study, 17 women (age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrasonography (US) immediately before therapy and at completion of 10%, 60%, and 100% of chemotherapy. All patients provided written informed consent...
May 3, 2017: Radiology
https://www.readbyqxmd.com/read/28464832/the-e2f4-prognostic-signature-predicts-pathological-response-to-neoadjuvant-chemotherapy-in-breast-cancer-patients
#20
Kenneth M K Mark, Frederick S Varn, Matthew H Ung, Feng Qian, Chao Cheng
BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor's disease pathology. Developing genomic clinical assays that accurately categorize responders from non-responders can provide patients with the most effective therapy for their individual disease. METHODS: We applied our previously developed E2F4 genomic signature to predict neoadjuvant chemotherapy response in breast cancer...
May 2, 2017: BMC Cancer
keyword
keyword
105931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"